Stockscreener 앱 받기
1.73
0.00%
0.00
시간 외 거래:
1.73
Pulmatrix Inc 주식(PULM)의 최신 뉴스
PULMPulmatrix Inc Latest SEC Filings - Finviz
Enterprise value to EBITDA forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
(PULM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM) - TradingView
Pulmatrix Inc Actuals & Estimates (LS:A3DWEE) - TradingView
Enterprise value to revenue forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Price to earnings forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Enterprise value to EBITDA forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
PULM Q2 2025 Earnings: Clinical‑Stage Biotech Reports Loss Per Share of $0.42, No RevenueEBITDA Estimate Trend - dars.gov.et
Price to earnings forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
Enterprise value to EBIT forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmatrix Inc (PULM) Institutional Confidence - TradingKey
Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4% - Stock Titan
PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue AbsenceConsensus Forecast Report - newsline.com
PULM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulmatrix Q2 2025 Earnings: Loss Per Share of $0.42 as Clinical Pipeline AdvancesEarnings Preview - newsline.com
Pulmatrix Q2 2025 Earnings: Net Loss of $0.42 per Share as Biotech Continues Pipeline DevelopmentReturn On Capital - newsline.com
PULM Q2 2025 Earnings: Clinical-Stage Biotech Reports EPS of -$0.42Revenue Inflection Point - newsline.com
Pulmatrix Inc. (PULM) Q2 2025 Earnings: Narrowing Losses Amid Clinical MilestonesCore Business Growth - newsline.com
Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track - Stock Titan
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum - GlobeNewswire Inc.
Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends - Stock Titan
Pulmatrix Stock Slides As Eos Merger Clock Starts To Matter For PULM Holders - Bez Kabli
PULM Q2 2025 Earnings: Reported Loss of $0.42 per Share as Company Advances Pipeline - dars.gov.et
PULM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmatrix (PULM) Gains 1.47% as Shares Approach Key Resistance LevelIntraday Trade Ideas - The Legal Advocate
Pulmatrix Inc. (PULM) Edges Higher as Stock Gains 3.68% – Key Levels in FocusProfitability Factor - The Legal Advocate
Pulmatrix Inc. (PULM) Holds Steady at $1.34 as Key Support and Resistance Levels TightenIsland Reversal - The Legal Advocate
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87% - The Legal Advocate
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
Pulmatrix Announces First Quarter 2026 Financial Results - Fidelity
TradingKey - TradingKey
Number of shareholders of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
The hidden strength in Pulmatrix (PULM) most investors miss (Volatility Increases) 2026-05-08Attention Stocks - newser.com
The hidden strength in Pulmatrix (PULM) most investors miss (Risk Aversion) 2026-05-08Crowd Entry Points - newser.com
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - Quantisnow
Pulmatrix (PULM) Stock: Is It Losing Market Strength |Shared Buy Zones - Newser
1.17%
2.48%
자본화:
|
볼륨(24시간):